Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

331
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
331
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-in-Human Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

相关实验视频

Updated: Jun 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

剂量优化:开发瘤学药物的监管前景

Atiqur Rahman1, Mirat Shah2, Stacy S Shord1

  • 1Division of Cancer Pharmacology II, Office of Clinical Pharmacology, Office of Translational Sciences, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clinical pharmacology and therapeutics
|July 29, 2024
PubMed
概括

在癌症治疗中优化药物剂量对于开发有效和耐受瘤疗法至关重要. 该项目旨在从传统的化疗剂量转向针对性,免疫和细胞疗法的个性化方法.

更多相关视频

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

相关实验视频

Last Updated: Jun 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 药物开发 药物开发

背景情况:

  • 优化药物剂量对于有效和耐受性良好的癌症治疗至关重要.
  • 目前用于细胞毒性化疗的剂量范式,对于新型向疗法,免疫疗法和细胞疗法是不够的.
  • 患者和倡导者对更耐受治疗的需求推动了改革的必要性.

研究的目的:

  • 改革瘤药物开发中的剂量优化和选择范式.
  • 为解决新癌症疗法目前剂量策略的局限性.
  • 突出在建立最佳剂量以改善患者的治疗结果方面面临的挑战和机会.

主要方法:

  • 审查从细胞毒性化疗到向,免疫和细胞疗法剂量所需的范式转变.
  • 在药物开发过程中分析有限剂量表征的影响.
  • 利用定量方法,创新的试验设计和监管支持.

主要成果:

  • 不充分的剂量表征可能导致耐受性差,试验失败和市场撤回.
  • 要考虑新型瘤学药物类别的独特属性,需要进行范式转变.
  • 在整个开发过程中对数据的反复分析对于有利的利益风险概况至关重要.

结论:

  • 采用新的剂量模式对于实现现代瘤治疗的全部潜力至关重要.
  • 优化剂量策略可以提高药物的有效性和患者的耐受性.
  • 及时获得有效的癌症药物取决于整个开发过程中的强大的剂量优化.